Triple therapy targets tough brain metastases in lung cancer
NCT ID NCT06431685
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing whether a combination of low-dose radiation to the whole brain, an immunotherapy drug (PD-1 inhibitor), and chemotherapy given directly into the spinal fluid can safely treat lung cancer that has spread to the lining of the brain and spinal cord. The trial will enroll 10 adults aged 18-75 whose cancer has not responded to standard treatments. Researchers will monitor side effects and check if the cancer shrinks or stops growing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Whole brain low-dose radiotherapy, pembrolizumab (PD-1 inhibitor), and pemetrexed (intrathecal chemotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with lung cancer that has spread to the brain and spinal cord lining, potentially improving survival and quality of life.
What could go wrong
This is a very early (Phase 1) and small study with only 10 participants, so results may not apply to everyone. The combination of treatments may cause serious side effects, including brain inflammation or nerve damage.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••